Table 2.

Summarizes various drugs and their mechanism of action to induce ferroptosis in therapy-resistant CSCs.

Drug	Mechanism	Tumor Type	References
Iron chelators	Degrades ferritin, promotes LIP expression, and induces HMOX-1 expression	Breast, ovarian, colorectal, pancreatic, cervical	[80,81,82,83,84]
SLC7A11 inhibitors	Inhibits cysteine uptake thereby reducing glutathione levels	Glioma, breast, lung, melanoma, cervical, prostrate, neuroblastoma	[25,78,79]
GPx-4 inhibitors	Inhibit the enzyme activity of GPx-4 thereby enhancing lipid peroxides	Leukaemia, lymphoma, sarcoma, ovarian cancer, pancreatic, lung	[85,86,87]
Cysteinase	Glutathione inhibitor that degrades cysteine and cystine	Prostrate, pancreatic, chronic lymphocytic leukaemia	[88,89]
FINO2	Indirectly inactivates GPx-4; promotes ROS accumulation by oxidizing PUFAs and ferrous iron	Fibrosarcoma	[90,91]